VOLITIONRX LTD

VolitionRx Limited reported a net loss attributable to stockholders of $(7.33) million for Q2 2026, compared to $(6.28) million in Q2 2025. Total revenues for the quarter were $398,657, a slight decrease from $406,688 in the prior year. The company completed a one-for-twenty reverse stock split in April 2026. Despite continued losses, cash and cash equivalents increased significantly due to financing activities, and the net loss per share improved.

VolitionRx Limited announced its second quarter 2026 financial results and business updates. The company reported Q2 revenue of $0.4 million, in line with the prior year, while significantly reducing operating expenses by 32% and operating loss by 34% to $4.2 million. First half 2026 revenue saw substantial growth of 112% to $1.4 million. Key business developments include a collaboration with Sysmex, submission of a clinical manuscript for its feline lymphoma assay with a potential $5 million milestone, and ongoing discussions for licensing agreements. A conference call to discuss these results is scheduled for August 14, 2026.

VolitionRx Limited issued a total of 779,371 shares of common stock to Lind Global Asset Management XII LLC across three transactions in July and August 2026. These issuances satisfied payment and conversion obligations totaling approximately $750,000, stemming from previously issued senior secured convertible promissory notes. The shares were issued under exemptions from registration requirements of the Securities Act of 1933.

VolitionRx Limited filed an amendment to its Certificate of Incorporation to reduce the number of authorized shares of common stock from 325,000,000 to 150,000,000. This amendment was approved by stockholders at the 2026 annual meeting held on July 17, 2026. During the meeting, stockholders also elected seven directors, ratified the independent auditor, approved executive compensation, and approved the 2026 Stock Incentive Plan.

VolitionRx Limited issued a total of 545,591 shares of common stock to Lind Global Asset Management XII LLC to satisfy $833,332 in payment obligations under a senior secured convertible promissory note. Specifically, 333,332 shares were issued on June 17, 2026, for a $416,666 payment, and 212,259 shares were issued on May 19, 2026, for another $416,666 payment. These shares were issued to an existing securityholder in reliance on exemptions from the Securities Act, without a public offering.

VolitionRx Limited announced the pricing of its public offering, selling 2,960,000 shares of common stock along with warrants to purchase an additional 1,480,000 shares. The combined offering price was $1.55 per share and accompanying warrant, resulting in approximately $4.1 million in net proceeds. The company plans to use these funds for research, product development, clinical studies, commercialization, working capital, and repayment of convertible notes. Maxim Group LLC served as the sole placement agent.

VolitionRx Limited has filed its Definitive Proxy Statement (DEF 14A) for its 2026 Annual Meeting of Stockholders, scheduled for July 17, 2026. The meeting agenda includes the election of directors, ratification of its independent registered public accounting firm, an advisory vote on executive compensation, a proposal to reduce authorized shares from 325,000,000 to 150,000,000, and the approval of the 2026 Stock Incentive Plan. The company also disclosed that a one-for-twenty reverse stock split was effected on April 28, 2026, and provided details on significant shareholdings, including Lagoda Investment Management, L.P. (9.8%) and Lind Global Asset Management XII LLC (4.99%).

VolitionRx Limited failed to comply with the Market Capitalization Covenant related to its senior secured convertible promissory notes held by Lind Global Asset Management XII LLC. On May 21, 2026, Lind issued a waiver, preventing it from exercising certain rights and remedies such as accelerating obligations or foreclosing on collateral. However, the company is now required to pay an additional 10% of the outstanding principal amount of each note, and Lind gained more favorable terms for converting the notes into common stock.

VolitionRx Limited announced that Mickie Henshall will not seek re-election to its Board of Directors at the 2026 Annual Meeting. Ms. Henshall has been a board member since August 2022, and her decision was not due to any disagreements with the company's operations or policies. As a result, the Board will reduce its size from eight to seven directors, effective immediately prior to the 2026 Annual Meeting.

VolitionRx reported a net loss of $6.7 million for the first quarter of 2026, an increase from $5.5 million in the prior year, despite total revenues significantly rising to $985,076. The company's auditors continue to express substantial doubt about its ability to continue as a going concern. Subsequent to the quarter, VolitionRx completed a one-for-twenty reverse stock split and raised approximately $0.6 million through common stock sales.